| ●Round table discussion | ||
| Ethics in clinical trial in the days of globalization of drug development | Robert J. Levine, Tsutani K, Sakanoue M, et al. | 341-80 |
| ＜Materials＞ | ||
| The debate over maternal-fetal HIV transmission prevention trials in developing countries | Sato K | 381-5 |
| The Belmont Report | ||
| [Japanese] ※Full Japanese translation is published in Vol.28 No. 3 | 387-90 | |
| [English] | 391-4 | |
| Recent movement at the World Medical Association on revision of the Helsinki Declaration |
Sakanoue M | 395-408 |
| World Medical Association Declaration of Helsinki | ||
| [Japanese] | 409-12 | |
| [English] | 413-7 | |
| ●Original | ||
| Clinical utility of TJ-960 in patients with localization related epilepsy －Late phaseⅡ study：Multicenter, double-blind study in comparison with placebo－ | Nakane Y, Yamauchi T, Onuma T, et al. | 419-52 |
| ●Report | ||
| 50 years of clinical trials －Past, present and future－ | Shimizu N, Tsutani K | 453-74 |
| The third party guarantee system in 798 double blind randomized controlled trials in Japan |
Shimizu N, Satoh Y, Kurihara M, et al. |
475-85 |
| Ethnic difference：How the data from randomized controlled trials can be utilized between different ethnic groups |
Uchida E, Naito C | 487-503 |
| ●Materiasl | ||
| Conflict of interest in the debate over calcium-channel antagonists | trans. by Mitsuishi T | 505-15 |
| Ethnic factors in the acceptability of foreign clinical data | 517-43 | |
| ●Errata | 545-6 | |
| ●Editor's note | 547 | |
| ●Notice to authors | 548 | |